Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis

被引:220
作者
Bain, MA [1 ]
Faull, R
Fornasini, G
Milne, RW
Evans, AM
机构
[1] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst, Pharmaceut Res Ctr, Adelaide, SA 5000, Australia
[2] Royal Adelaide Hosp, Renal Unit, Adelaide, SA 5000, Australia
[3] Sigma Tau Pharmaceut Inc, Gaithersburg, MD USA
关键词
end-stage renal disease; gas chromatography; trimethylamine; trimethylamine-N-oxide;
D O I
10.1093/ndt/gfk056
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Trimethylamine (TMA) is a short-chain tertiary aliphatic amine that is derived from the diet either directly from the consumption of foods high in TMA or by the intake of food high in precursors to TMA, such as trimethylamine-N-oxide (TMNO), choline and l-carnitine. The clinical significance of TMA may be related to its potential to contribute to neurological toxicity and 'uraemic breath' in patients with end-stage renal disease (ESRD). Methods. Concentrations of TMA and TMNO in plasma from 10 healthy adults (not on haemodialysis) and 10 adults with ESRD undergoing haemodialysis (pre- and post-dialysis) were determined by gas chromatography-mass spectrometry. Results. The concentrations of TMA and TMNO in pre-dialysis plasma (1.39 +/- 0.483 and 99.9 +/- 31.9 mu M, respectively) were significantly (P < 0.05) higher than the corresponding levels in healthy subjects (0.418 +/- 0.124 and 37.8 +/- 20.4 mu M, respectively). However, there were no significant differences between post-dialysis and healthy subject plasma concentrations. In the ESRD patients, there was a significant (P < 0.05) reduction in plasma TMA (from 1.39 +/- 0.483 to 0.484 +/- 0.164 mu M) and TMNO (from 99.9 +/- 31.9 to 41.3 +/- 18.8 mu M) during a single haemodialysis session. Conclusions. TMA and TMNO accumulate between haemodialysis sessions in ESRD patients, but are efficiently removed during a single haemodialysis session.
引用
收藏
页码:1300 / 1304
页数:5
相关论文
共 20 条
[1]   PHARMACOKINETICS OF TRIETHYLAMINE AND TRIETHYLAMINE-N-OXIDE IN MAN [J].
AKESSON, B ;
VINGE, E ;
SKERFVING, S .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1989, 100 (03) :529-538
[2]   THE METABOLISM OF C-14-LABELED TRIMETHYLAMINE AND ITS N-OXIDE IN MAN [J].
ALWAIZ, M ;
MITCHELL, SC ;
IDLE, JR ;
SMITH, RL .
XENOBIOTICA, 1987, 17 (05) :551-558
[3]   Quantifying trimethylamine and trimethylamine-N-oxide in human plasma:: interference from endogenous quaternary ammonium compounds [J].
Bain, MA ;
Faull, R ;
Fornasini, G ;
Milne, RW ;
Schumann, R ;
Evans, AM .
ANALYTICAL BIOCHEMISTRY, 2004, 334 (02) :403-405
[4]   Validation of liquid chromatographic and gas chromatographic methods - Applications to pharmacokinetics [J].
Bressolle, F ;
BrometPetit, M ;
Audran, M .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 686 (01) :3-10
[5]  
Cashman JR, 2001, DRUG METAB DISPOS, V29, P1629
[6]  
Cengiz Kuddusi, 2002, International Urology and Nephrology, V33, P121
[7]  
Hecht SS, 1997, P SOC EXP BIOL MED, V216, P181
[8]  
IHLE BU, 1984, CLIN NEPHROL, V22, P82
[9]   Isoform specificity of trimethylamine N-oxygenation by human flavin containing monooxygenase (FMO) and P450 enzymes -: Selective catalysis by FMO3 [J].
Lang, DH ;
Yeung, CK ;
Peter, RM ;
Ibarra, C ;
Gasser, R ;
Itagaki, K ;
Philpot, RM ;
Rettie, AE .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (08) :1005-1012
[10]   Quantitative determination of trimethylamine in urine by solid-phase microextraction and gas chromatography mass spectrometry [J].
Mills, GA ;
Walker, V ;
Mughal, H .
JOURNAL OF CHROMATOGRAPHY B, 1999, 723 (1-2) :281-285